Lymphocyte Phenotypes and Protein-Bound Uremic Toxins as Determinants of Clinical Outcomes in Hemodialysis Patients
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110376 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Theodoros Tourountzis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Protypo Dialysis Center of Thessaloniki, 55535 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Renal Dialysis, Uremic Toxins, Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The impact of protein bound uremic toxins (PBUTs) and lymphocyte alterations in morbidity and mortality in patients on hemodialysis (HD) is of great concern. The aim of this study was the assessment of association between PBUTs, immunosenescent lymphocytes’ phenotype and clinical events [cardiovascular, severe infections (hospitalization due to infection, respiratory infection), all-cause mortality] during 2-year follow-up. In this prospective observational study, lymphocytes’ phenotype of 54 patients on HD and 31 age-matched controls was analyzed by flow cytometry, and simultaneously, PBUT serum levels [hippuric acid (HA), indoxyl sulfate (IxS), p-cresyl sulfate (pCS), p-cresyl glycuronide (pCG), in-dole-3-acetic acid (IAA), and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF)] were quantified by ultra-performance liquid chromatography. Patients with increased levels of free IxS and total and free HA had higher mortality within a 2-year follow-up period (p = 0.049, p = 0.01, p = 0.01, respectively). In patients who experienced cardiovascular events, higher concentrations of CMPF (p = 0.015) were observed. Higher total and free HA levels associate with increased all-cause mortality in patients on HD, independently of age, dialysis vintage, and decreased count of CD4+CD45RA+CD31+ and naïve B cells (CD19+IgD+CD27−). In patients on HD, increased levels of total and free HA associate with an increased risk of death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Protypo Dialysis Center of Thessaloniki, 55535 Thessaloniki, Greece.
- Department of Nephrology, School of Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokratio", 54642 Thessaloniki, Greece.
- Department of Internal Medicine and Pediatrics, Nephrology Unit, Ghent University Hospital, 9000 Gent, Belgium.
- Department of Immunology, National Peripheral Histocompatibility Center, General Hospital "Hippokratio", 54642 Thessaloniki, Greece.
- Department of Nephrology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
ORCID-Profile: Theodoros Tourountzis, Stamatia Stai, Steven Van Laecke, Eleni Moysidou, Michalis Christodoulou, Griet Glorieux, Maria Stangou
Zitieren
APA
Tourountzis, T., Lioulios, G., Stai, S., Laecke, S. V., Moysidou, E., Christodoulou, M., Fouza, A., Fylaktou, A., Kantartzi, K., Glorieux, G., & Stangou, M. (2025). Lymphocyte Phenotypes and Protein-Bound Uremic Toxins as Determinants of Clinical Outcomes in Hemodialysis Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110376
Vancouver
Tourountzis T, Lioulios G, Stai S, Laecke SV, Moysidou E, Christodoulou M, et al. Lymphocyte Phenotypes and Protein-Bound Uremic Toxins as Determinants of Clinical Outcomes in Hemodialysis Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110376
BibTeX
@article{Tourountzis2025,
author = {Tourountzis, Theodoros and Lioulios, Georgios and Stai, Stamatia and Laecke, Steven Van and Moysidou, Eleni and Christodoulou, Michalis and Fouza, Ariadni and Fylaktou, Asimina and Kantartzi, Konstantia and Glorieux, Griet and Stangou, Maria},
title = {Lymphocyte Phenotypes and Protein-Bound Uremic Toxins as Determinants of Clinical Outcomes in Hemodialysis Patients},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110376}
}
EUVIMED